Navigation Links
$9.1 million grant to improve drug therapy using gene profiles
Date:9/8/2010

COLUMBUS, Ohio The National Institute of General Medical Sciences has awarded a $9.1 million, five-year grant to The Ohio State University for a study titled "Expression Genetics in Drug Therapy." The goal of the research is to enhance drug response rates and reduce the number of adverse drug reactions among patients taking medication.

The grant also funds Ohio State as a member of a nationwide Pharmacogenomics Research Network (PGRN), which connects 14 major centers across the United States with diverse specializations, working jointly to achieve this goal.

"It's estimated that 30 percent to 70 percent of people who take medication do not respond favorably and even have serious adverse reactions to it," says study leader Wolfgang Sadee, chair and professor of pharmacology, of pharmacy, of internal medicine, of psychiatry and of public health at The Ohio State University. Sadee also chairs Ohio State's Program in Pharmacogenomics.

Sadee notes that adverse drug reactions are a major cause of death and hospitalization in the United States. "We want to improve our ability to give the right drug to the right patient at the right time at the right dosage," adds Sadee.

"Because people are genetically different, they respond differently to medication," he says. "If we can identify these genetic differences, then we can prevent adverse drug reactions and predict which drugs will offer the best treatment for individual patients."

But critical genetic differences among individuals largely remain unknown, Sadee says. "Our project uses a novel approach to finding these critical genetic differences and testing them immediately in clinical trials that are under way here at Ohio State and across the world." The project will also support large-scale DNA sequencing using the latest technologies, enabling researchers to study the entire human genome.

The study led by Sadee targets genes that are important for major diseases such as central nervous system disorders, cardiovascular disease, cancer, and their therapies. It further includes new projects driven by a clinical need, such as nephritic syndrome in children to understand why some children do not respond to standard therapy.

The project involves collaborations with researchers at The Ohio State University Dorothy Davis Heart and Lung Research Institute, Ohio State's Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute, Nationwide Children's Hospital in Columbus, and at medical centers in the US, Canada, and Europe.

Ohio State's pharmacogenomics program, directed by Sadee, studies genetic factors that determine the activity of drug receptors and metabolizing enzymes, critical elements in a patient's response to most drugs in current use. The research is designed to identify clinically useful biomarkers that will help identify people who, because of their genetic make-up, respond to or metabolize drugs in ways that alter the drug's activity in the body, according to Sadee, a specialist in pharmacogenomics, a field that investigates the genetic basis for variations in drug response.

Some people, for example, may be genetically predisposed to respond to a particular drug to an unusual high degree. Such individuals would need a lower-than-usual dose of drug to avoid serious side effects. Other people may have genes that reduce drug response and may need a higher-than-usual dose to benefit from the drug. And some people may lack an enzyme entirely that is needed to metabolize a particular drug. These individuals are potentially at risk and should receive a different agent altogether.

"We are applying genome sequencing and other fundamentally new approaches to identify biomarkers that will make drugs more efficient and prevent side effects," Sadee says. The Sadee group has already identified a series of clinically promising pharmacogenetic biomarkers as potential guides in a person's therapy.

The 14 research groups within the PGRN are studying the effects of genes on people's responses to a wide variety of medicines. Each group is independently funded by the National Institute of General Medical Sciences and multiple other institutes of the NIH, and focuses on a particular area of pharmacogenomics.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related biology news :

1. UCSF receives $15 million to advance personalized medicine
2. UT Health Science Center San Antonio lands $11.6 million to study cardiac proteins
3. University of Arizona-led group awarded $9.9 million to develop super rice
4. Why does anxiety target women more? FSU researcher awarded $1.8 million grant to find out
5. Jefferson receives $3 million NIH grant to study molecular and genetic mechanisms in platelets
6. IU physics facility awarded $5 million for cooperative neutron research
7. $7 million grant designates Nationwide Childrens as Wellstone Center
8. New study shows how giant tortoises, alligators thrived in High Arctic 50 million years ago
9. Fossil reveals 48-million-year history of zombie ants
10. University of Maryland School of Medicine receives $7.9 million grant for super research magnet
11. Mosasaur fossil at Natural History Museum of L.A. County re-explores 85-million-year-old sea monster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology: